The class XIV myosin of Toxoplasma gondii, TgMyoA, is druggable in an animal model of infection
A. Kelsen, R. S. Kent, A. K. Snyder, E. Wehri, S. J. Bishop, R. V. Stadler, C. Powell, B. Martorelli di Genova, P. K. Rompikuntal, M. J. Boulanger, D. M. Warshaw, N. J. Westwood, J. Schaletzky, G. E. Ward
Abstract
Toxoplasma gondii is a widespread apicomplexan parasite that can cause severe disease in its human hosts. The ability of T. gondii and other apicomplexan parasites to invade into, egress from, and move between cells of the hosts they infect is critical to parasite virulence and disease progression. An unusual and highly conserved parasite myosin motor (TgMyoA) plays a central role in T. gondii motility. The goal of this work was to test whether pharmacological inhibition of TgMyoA can alter disease progression in an animal model of infection. To this end, we sought to identify small molecule inhibitors of TgMyoA by screening a collection of 50,000 structurally diverse small molecules for inhibitors of the recombinant motors actin-activated ATPase activity. The top hit to emerge from the screen, KNX-002, inhibited TgMyoA with little to no effect on any of the vertebrate myosins tested. KNX-002 was also active against parasites, inhibiting parasite motility and growth in culture in a dose-dependent manner. We used chemical mutagenesis, selection in KNX-002, and targeted sequencing to identify a mutation in TgMyoA (T130A) that renders the recombinant motor less sensitive to compound. Compared to wild-type parasites, parasites expressing the T130A mutation showed reduced sensitivity to KNX-002 in motility and growth assays, confirming TgMyoA as a biologically relevant target of KNX-002. Finally, KNX-002 was shown to slow disease progression in mice infected with wild-type parasites, but not parasites expressing the resistance-conferring TgMyoA T130A mutation. These data demonstrate the specificity of KNX-002 for TgMyoA, both in vitro and in vivo, and validate TgMyoA as a druggable target for toxoplasmosis. Since TgMyoA is essential for virulence, conserved in apicomplexan parasites, and distinctly different from the myosins found in humans, pharmacological inhibition of MyoA offers a promising new approach to treating the devastating diseases caused by T. gondii and other apicomplexan parasites.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of UCB-9721 as a potent inhibitor of MyoA, the essential class XIV myosin motor of apicomplexan parasites
Anne K Snyder, Filomena Tedesco, … Gary E. Ward·bioRxiv·Jun 19, 2026
- Pentachloropseudilin disrupts multiple steps of the Toxoplasma gondii lytic cycle, consistent with predicted multi-myosin engagement
Romane AGRESTI, Faraj GTAT, … Isabelle Tardieux·bioRxiv·Oct 1, 2026
- Blocking palmitoylation of Toxoplasma gondii myosin light chain 1 disrupts glideosome composition but has little impact on parasite motility
P. K. Rompikuntal, I. T. Foe, … G. E. WARD·bioRxiv·Aug 13, 2020
- Motility-dependent processes in Toxoplasma gondii tachyzoites and bradyzoites: same same but different
Robyn S. Kent, Gary E. Ward·mSpherePeer-reviewed·Feb 12, 2025
- The Toxoplasma Acto-MyoA Motor Complex Is Important but Not Essential for Gliding Motility and Host Cell Invasion
Saskia Egarter, Nicole Andenmatten, … Markus Meissner·PLoS ONEPeer-reviewed·Mar 14, 2014
- Screening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoites.
Deborah Maus, Elyzana Putrianti, … Martin Blume·bioRxiv·Nov 23, 2023